<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854097</url>
  </required_header>
  <id_info>
    <org_study_id>1-014-18</org_study_id>
    <nct_id>NCT03854097</nct_id>
  </id_info>
  <brief_title>Effect of Intermittent Pressure in Patients With PAD</brief_title>
  <official_title>Mechanistic Insights Into Changes in Blood Flow Following Application of Intermittent Negative Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of intermittent negative pressure (INP) on peripheral
      arterial disease (PAD) patient vascular function and blood flow. Patients will be given
      either -40mmHg INP or -10mmHg INP which will act as a placebo. Healthy volunteers will be
      given -40mmHg INP to evaluate changes in vascular function and blood flow with INP in healthy
      physiology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis occurs when blood supply to the lower limbs is restricted upon accumulation
      of fat in the arteries. Atheroslerosis in the lower limbs is termed peripheral arterial
      disease (PAD). The initial symptom is pain in the lower limbs followed by ulceration and
      gangrene. The literature has indicated that intermittent negative pressure (INP) can be used
      to reduce pain and facilitate wound healing. INP is a non-invasive technique that aims to
      increase arterial and skin blood flow in lower limbs and foot. This study aims to investigate
      the underlying mechanisms that are involved in changes in blood flow following application of
      INP. The Flow-Ox 'boot' will be used to apply INP for periods ranging from 4-8 weeks, for an
      hour twice per day, to the lower limb to determine the effects of INP on vascular function
      and blood flow. Specifically, vascular tests such as assessments of endothelial function,
      arterial stiffness, ankle-brachial pressure index (ABPI) and blood borne metabolic and
      inflammatory markers will be performed before and after INP application. A pain chart will be
      employed before and after INP application to determine whether there is any change in
      perception of pain felt by individuals who suffer from pain associated with lower limb
      arterial disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microvascular blood flow</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Microvascular blood flow measurement in foot using laser Dopper imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in microvascular endothelial function</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Peak blood perfusion response to acetylcholine (ACh) delivered by iontophoresis will be measured using a laser Doppler imager.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in arterial stiffness</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Brachial pulse wave analysis (PWA) augmentation index (Ax) and carotid-femoral pulse wave velocity (m/s) (PWV) as an indication of arterial stiffness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in macrovascular endothelial function</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Brachial endothelial function measured as change in brachial blood vessel diameter (%) upon shear stress.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain score</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Self-scoring of pain felt by patient on a visual analogue scale with 0 being no pain at all to 10 being the worst pain ever felt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of blood borne inflammatory and oxidative stress biomarkers</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Concentration of inflammatory and oxidative stress markers of endothelial activation/damage (including IL-1a, IL-6, IL-10, TNF-a, CRP, E-selectin and sICAM-1) measured in serum and plasma collected from patient blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle-Brachial Pressure Index (ABPI)</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Brachial systolic pressure and ankle (dorsalis pedis) systolic pressure (mmHg) measured using Doppler probe. ABPI calculated as ankle systolic pressure divided by brachial systolic pressure.
ABPI &lt;0.9 = PAD, ABPI =&gt;1.0 Normal.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Active PAD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo PAD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-40 mmHg of Intermittent Negative Pressure (INP) for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Intermittent Negative Pressure (INP)</intervention_name>
    <description>Application of -40mmHg negative pressure on the lower limb</description>
    <arm_group_label>Active PAD group</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Intermittent Negative Pressure (INP)</intervention_name>
    <description>Application of -10mmHg negative pressure on the lower limb</description>
    <arm_group_label>Placebo PAD group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        PAD Patients:

          -  Age ≥ 18 years

          -  Attending vascular outpatient clinics or admitted in ward with PAD.

          -  ABPI &lt;0.9

        Healthy Volunteers:

          -  Age ≥ 18 years

          -  No current or previous significant cardiovascular illness

          -  Able to give written informed consent

        Exclusion criteria

        PAD Patients:

          -  Unable to give written informed consent

          -  Patients with deep venous thrombosis

          -  Pregnant women

        Healthy Volunteers:

          -  Positive medical history of: Vascular diseases such as PAD, stroke, IHD,
             hypertension... etc.

          -  Haematological conditions such as hypercoagulability, deep venous thrombosis... etc.,

          -  Alcohol excess

          -  Unable to give written informed consent

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jody McIntosh</last_name>
    <role>Principal Investigator</role>
    <affiliation>PhD Student</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faisel Khan, PhD</last_name>
    <phone>01382 383531</phone>
    <email>f.khan@dundee.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>School of Medicine, University of Dundee, Ninewells Hospital &amp; Medical School</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisel Khan, PhD</last_name>
      <phone>01382383531</phone>
      <phone_ext>83531</phone_ext>
      <email>f.khan@dundee.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Jody McIntosh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muhammad S Hussain</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stuart A Suttie, MBChB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gillian Mudie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03854097/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

